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Head and neck cancer (HNC) is a preventable malignancy that continues to cause substantial morbidity and mortality world-wide. 
Using data from the ARCAGE and Rome studies, we investigated the main predictors of survival after larynx, hypophar-ynx and oral 
cavity (OC) cancers. We used the Kaplan–Meier method to estimate overall survival, and Cox proportional models to examine the 
relationship between survival and sociodemographic and clinical characteristics. 604 larynx, 146 hypopharynx and 460 OC cancer 
cases were included in this study. Over a median follow-up time of 4.6 years, nearly 50% (N 5 586) of patients died. Five-year survival 
was 65% for larynx, 55% for OC and 35% for hypopharynx cancers. In a multivariable analy-sis, we observed an increased mortality 
risk among older ( 71 years) versus younger ( 50 years) patients with larynx/hypo-pharynx combined (LH) and OC cancers [HR 5 1.61, 
95% CI 1.09–2.38 (LH) and HR 5 2.12, 95% CI 1.35–3.33 (OC)], current versus never smokers [HR 5 2.67, 95% CI 1.40–5.08 (LH) 
and HR 5 2.16, 95% CI 1.32–3.54 (OC)] and advanced versus early stage disease at diagnosis [IV versus I, HR 5 2.60, 95% CI 1.78–
3.79 (LH) and HR 5 3.17, 95% CI 2.05–4.89 (OC)]. Survival was not associated with sex, alcohol consumption, education, oral health, 
p16 expression, presence of HPV infection or body mass index 2 years before cancer diagnosis. Despite advances in diagnosis and 
therapeutic modalities, survival after HNC remains low in Europe. In addition to the recognized prognostic effect of stage at diagnosis, 
smoking history and older age at diagnosis are important prognostic indicators for HNC. 
What’s new?  
Most people diagnosed with head and neck cancer do not survive to the 8-year mark. These authors examined which factors correlate 
with survival after cancer of the larynx, hypopharynx or oral cavity. They found increased mortality among patients over age 70 
years, current smokers, and those with advanced disease. Stage at diagnosis is one of the strongest predictors of survival, but even 
with modern detection methods, most patients in Europe are still diagnosed with advanced disease. 
 
Head and neck cancer (HNC) is mostly comprised of oral cavity, oropharynx, hypopharynx and larynx tumors. When 
taken together, HNC represents the fifth most common malignancy in males in the high-income countries, with a lower 
incidence among females (male-to-female ratio varies from 2:1 to 4:1).1 Over 90% of cases are squamous cell carci-
nomas.2 HNC can be cured if the tumor is diagnosed at early stage and limited to the head and neck region. However, 
prognosis is very poor when HNC is diagnosed at later stages with metastatic or recurrent disease. A decision between 
aggressive multimodality and function-preserving treatment should be based on patient’s health and comorbidities, and 
on the extent to which therapy may affect the patient’s qual-ity of life.3  
Tobacco exposure (including active and smokeless tobacco use) and alcohol consumption are well-established risk fac-
tors for HNC.4 Human Papillomavirus (HPV) infection is an additional independent risk factor for oropharynx cancer. 
Studies have shown that HPV-related HNC is genetically and biologically different from smoking-associated HNC, with 
HPV-related HNC demonstrating improved clinical out-comes.3 HPV-positive oropharynx cancer patients commonly 
have greater survival than HPV negative cases.5–7 However, the same HPV causal and prognostic associations have 
not been observed for larynx, hypopharynx or oral cavity cancer where HPV infections are rare.8  
Stage at diagnosis has been considered one of the stron-gest predictors of survival among patients with HNC,9 whereas 
the role of smoking and alcohol on survival remains controversial. Robust epidemiological data may help to iden-tify 
modifiable prognostic factors and guide cancer preven-tion programs aimed to reduce the burden of HNC worldwide.10 
In this study, we focused on the determinants of survival from larynx, hypopharynx and oral cavity cancers in Europe. A 
separate study has examined survival from oro-pharynx cancer including the role of HPV.11 
 
Patients and Methods  
Patients  
Data were obtained from 14 centers located in 9 European countries. Thirteen centers were participants of the Alcohol-
Related Cancers and Genetic Susceptibility in Europe (ARCAGE) case-control study12 as follows: Czech Republic 
(Prague), Germany (Bremen), Greece (Athens), Italy (Aviano, Padova and Turin), Ireland (Dublin), Norway (Oslo), United 
Kingdom (Glasgow, Manchester and Newcastle), Spain (Bar-celona) and Croatia (Zagreb). The remaining data were 
obtained from a case–control study in Rome.13 The recruit-ment of cases was performed from 2002 to 2005 for the 
ARCAGE study (n 5 1,066) and from 2003 to 2011 for the  
Rome study (n 5144). Details of the ARCAGE and Rome projects can be found elsewhere.12,13  
Cases eligible for inclusion in our study were all patients with a primary squamous cell carcinoma of the larynx, hypo-
pharynx or oral cavity confirmed by histology or cytology. We included the following topography codes from the Inter-
national Classification of Diseases for Oncology, 3rd edition (ICD-O-3)14: C320–C32.9 for larynx, C12.9 and C13.0–
C13.9 for hypopharynx, and C00.3–C00.9, C02.0–C02.3, C03.0– C03.9, C04.0–C04.9, C05.0 and C06.0–C06.9 for oral 
cavity cancers. Following a standard protocol, participants under-went an identical questionnaire-based interview within 6 
months of diagnosis to obtain sociodemographic information, complete lifetime smoking and alcohol histories, dietary 
habits, dental health and care and education level attained. Biological samples (blood and/or tumor blocks) were also 
collected. Data on stage at diagnosis, overall treatment and clinical outcomes were subsequently obtained from 
population-based registries, medical records, linkage with regional or national death index and doctor’s contact. Partici-
pants were followed from the date of diagnosis to the date of death, loss to follow-up or end of study (December 31, 
2011), whichever occurred first. Patient’s follow-up was per-formed once from 2012 to 2015 to obtain last known vital 
status (alive, death or lost to follow-up) and date of last contact. 
 
Sociodemographic, clinical and lifestyle variables  
The sociodemographic, clinical and lifestyle variables were classified as follows. Age at diagnosis was categorized in 4 
groups ( 50, 51–60, 61–70 and 71 years). Tumor stage at diagnosis was classified in stages I–IV based on the TNM 
system of the American Joint Commission on Cancer (AJCC) Staging Manual, 6th edition.15 Smoking was examined in 
3 different ways: overall history (never, former or current smokers), duration (never, 1–9, 10–19, 20–29, 30–39 and 40 
years) or intensity (number of pack of cigarettes per year: never, <20, 20–39, 40–59 and 60). Smokers were individuals 
who used any tobacco product (estimated based on cigarette equivalents) at least once a week for one year. Alcohol 
consumption was also examined in 3 ways: overall history (never, former or current drinkers), duration (never, 1–9, 10–
19, 20–29, 30–39 and 40 years) and intensity (number of drinks per day: <5 or 5). Information on over-all smoking and 
alcohol histories were obtained from all cen-ters, whereas Rome did not have information on duration and intensity of 
these variables. Therefore, overall histories were included in the main models and separate models, excluding Rome 
cases, were performed to examine the effect of smoking and alcohol duration and intensity on survival, and were 
included in Supporting Information, Table S1.  
Education was categorized as level of education attained by the time of diagnosis: primary school, secondary school 
or university degree. Body mass index (BMI, kg/m2) was exam-ined using self-reported height and weight 2 years before 
cancer diagnosis, which decreases the probability that low BMI is secondary to cancer development.16 BMI was classi-
fied according to the World Health Organization into 4 cate-gories: underweight (<18.5), normal weight (18.5–24.9), 
overweight (25.0–29.9) and obese ( 30.0). Dental care and oral hygiene scores were created and classified as good, 
mod-erate and poor as described elsewhere.17  
Binary variables were sex (male/female) and the HPV tumor markers HPV16 DNA and p16 protein expression 
(positive/negative). HPV16 DNA genotyping was done using the type-specific E7 polymerase chain reaction bead-based 
multiplex assay (TS-E7-MPG, IARC, Lyon, France) as described elsewhere.17 The qualitative assessment of antigen 
p16INK4A was performed by immunohistochemistry, using the CINtec Histology kit according to the manufacturer’s 
instructions (www.mtmlabs.com). P16 expression was scored based on the intensity and the proportion of nuclear and 
cytoplasmic stained cells, and was considered positive when the combined score was equal to 4 or higher. Studies have 
shown that combined p16 expression and HPV16 DNA test-ing are needed to predict outcome for HNC.18 We examined 
p16 expression alone and combined with HPV16 DNA as follows: p16 (2) DNA (2), p16 (1) DNA (2), p16 (1) DNA (1) and 
p16 (2) DNA (1). In addition to the varia-bles above, we provided a descriptive analysis on relapse occurrence and 
overall treatment. 
 
Statistical analyses  
We used the Kaplan–Meier method to estimate 2-, 5- and 8-year overall (all-cause) survival, and used the log-rank test 
to examine differences in survival across strata of each variable. Overall survival is presented by anatomic site and, 
sample size allowing, by tumor subsite (glottis vs supraglottis, tongue vs other regions of the mouth, and pyriform sinus 
and other hypopharynx regions).  
Multivariable Cox regression models were used to obtain the hazard ratios (HR) of death and corresponding 95% con-
fidence intervals (CI). We used the likelihood ratio test as an overall significance test for the association of each indepen-
dent variable with the hazard ratio of death. We tested the proportional hazard (PH) assumption by examining log–log 
survival plots, and confirmed the results by using Schoen-feld’s global test. The PH assumption was met for all varia-bles 
in the multivariable models. We included in the multivariable models the variables with a priori hypothesized or previously 
observed associations with survival (sex, age and stage at diagnosis, smoking and alcohol histories, BMI 2 years before 
diagnosis, education level and dental care) and additionally adjusted for year of diagnosis. A separate model was 
performed to examine the association between HPV tumor markers and survival.  
Given the modest number of hypopharynx cases, they were pooled with larynx cases for the multivariable analysis. 
When we performed separate Cox models, we observed the same pattern of associations for both larynx and hypophar-
ynx cases, but with larger confidence intervals and p values for hypopharynx cases due to the smaller sample size. 
Cases from Rome did not provide data on education, BMI prediag-nosis and oral health. Missing data were handled by 
includ-ing them as “unknown” categories in the multivariable models (omitted in the tables). A complete analysis where 
missing data were excluded was also conducted, and similar results were obtained. We tested for interactions between 
tumor sites and each variable and found no significant inter-action. Statistical analyses were performed using Stata 14 
software (StataCorp, College Station, TX, USA), and two 2-sided p values of <0.05 was considered statistically 
significant.  
Ethics Approval  
The ARCAGE study was approved by the Ethical Review Board of the International Agency for Research on Cancer 
(IARC), and the respective local boards in the individual par-ticipating centers. The Rome study was approved by the 
ethi-cal committee of Fondazione Policlinico Universitario “A. Gemelli”. All participants provided written informed consent 
for their participation in the study. 
 
Results  
A total of 604 (50%) larynx, 146 (12%) hypopharynx, and 460 (38%) oral cavity cancer cases were included in this study. 
The sociodemographic and clinical characteristics of patients are summarized by anatomic site in Table 1. Overall, most 
of patients were males (82%), ever smokers (91%), and ever drinkers (93%), had a median age at diagnosis of 60 years, 
and were diagnosed with advanced stage disease (55% stages III or IV vs 45% stages I or II). 
 
Overall survival  
The median follow-up time was 4.6 years. Of 1,210 patients, nearly half (n 5 586) died over the course of follow-up. Five-
year survival was 65% for larynx (95% CI 61–69), 55% for oral cavity (95% CI 50–60) and 35% for hypopharynx (95% CI 
27–43) cancers (Tables 2A and 2B, Figure1A). When an adequate sample size was available, survival was also exam-
ined by anatomic subsite. Based on the log-rank test, we observed that 5-year survival was higher among patients with 
glottic versus supraglottic cancer (77% vs 58%), and for those with tumor of the tongue versus other regions of the 
mouth (63% vs 50%). There was no evidence of difference in sur-vival between patients with cancer of the pyriform sinus 
and other hypopharynx regions (Figs. 1b–1d).  
For all anatomic sites, we found strong evidence of an association between worse survival and smoking history (for-
mer or current smoker) (Tables 2A and 2B) or advanced stage disease at diagnosis (Tables 2A and 2B and Supporting 
Information, Figure S1). Among oral cavity cancer patients, we also found associations of lower survival with older age at 
diagnosis, male sex, lower level of education and low BMI 2 years before cancer diagnosis. There was no evidence of 
sur-vival differences by p16 protein expression alone or com-bined with HPV testing for any cancer site (Tables 2A and 
2B). Survival did not vary by cancer center or country (data not shown). 
 
Hazard ratio of death  
In a multivariable Cox regression analysis, in which all varia-bles were mutually adjusted for, we found—among larynx/ 
hypopharynx cases—an increased risk of death for hypophar-ynx versus larynx cancer (HR 52.29, 95% CI 1.79–2.94), 
older compared to younger patients ( 71 versus 50 years, HR 5 1.61, 95% CI 1.09–2.38), current versus never smokers 
(HR 52.67, 95% CI 1.40–5.08) and advanced versus early stage disease at diagnosis (IV vs I, HR 5 2.60, 95% CI 1.78– 
3.79). Similarly, among oral cavity cancer patients, we observed an increased risk of death for older compared to 
younger patients ( 71 vs 50 years, HR 52.12, 95% CI, HR 5 1.35–3.33; and 61–70 vs 50 years, HR 5 1.65, 95% CI 1.12–
2.44), current versus never smoker (HR 5 2.16, 95% CI  
1.32–3.54), and for those with advanced versus early stage at diagnosis (IV vs I, HR 5 3.17, 95% CI 2.05–4.89) (Table 
3). We did not find significant associations between the risk of death and sex, dental care or BMI 2 years prediagnosis.  
In separate analyses, when we used the number of packs of cigarettes smoked per year or duration of smoking 
instead of overall smoking history (Rome cases excluded), similarly strong associations were found. For instance, 
larynx/hypo-pharynx patients who smoked 20 cigarette pack years had approximately 3 times higher risk of death than 
never smok-ers. Similarly, for oral cavity cancer, patients who smoked 20 cigarette pack years had a risk of death about 
2.5 times higher than never smokers (Supporting Information, Table S1). When we examined alcohol duration and 
intensity, we also did not find evidence of an association between the risk of death and alcohol consumption (Supporting 
Information, Table S1). There was no evidence of an association between the risk of death and p16 expression, whether 
examined alone or combined with HPV16 DNA testing (Figure 2 and Supporting Information, Table S2). 
 
Descriptive analysis  
Data on relapse was available for 80% of cases. Out of 973 patients, 341 (35%) relapsed. Higher incidence of relapse 
was observed among patients with hypopharynx (46%), followed by oral cavity (38%) and larynx (30%) cancers (p 5 
0.002). After excluding cases to whom relapse occurred <90 days from diagnosis (n 5 49), we observed that the majority 
of patients (n 5 194, 72%) relapsed within 2 years of HNC diag-nosis, whereas 19% (n 552) and 9% (n 5 25) relapsed 
within >2 to 5 years and >5 to 10 years, respectively (Supporting Information, Figure S2). Time to relapse did not differ 
signif-icantly by anatomic site.  
Overall information on type of treatment was available for 97% of cases. Surgery was performed in most of patients 
(74%), alone (34%) or combined with radiotherapy (28%), chemotherapy (1%), or both (11%). About 12% of patients 
received radiotherapy alone, 10% received chemotherapy and radiotherapy and 1% received chemotherapy alone. For 
about 2% of patients, no type of treatment was reported. 
 
Discussion  
Our results reveal that survival from head and neck cancer remains low in Europe. Except for patients with tumors of the 
glottis, 8-year survival was lower than 50% for all tumor sites and subsites. In the multivariable analyses, the main 
predictors of survival were age at diagnosis, stage at diagno-sis, smoking history and anatomic site. 
Age at diagnosis is often considered an independent pre-dictor of outcome for many types of cancer.19,20 The influ-  
ence of age on HNC survival remains controversial. In a recent review, which included surgical, radiation-alone and 
chemoradiation studies from 1980 to 2012, the authors con-cluded that even though elderly patients may experience 
higher treatment-related toxicities than their younger coun-terparts, there was not sufficient evidence that survival is 
worse among older than younger patients (the majority of the studies investigated overall rather than disease-free or 
cancer-specific survival).21 Another study which use data from the Surveillance Epidemiology and End Results (SEER) 
program in the United States (US) and estimated overall sur-vival of patients diagnosed with larynx, tongue or tonsil can-
cer between 1988 and 1998, supported these findings.22  
In contrast, our findings of increased risk of death among older patients ( 71 years for larynx/hypopharynx and 61 years 
for oral cavity cancers) support the results of several population-based studies in Europe and in the US. For instance, a 
European study used data from 15 French cancer registries on patients diagnosed with HNC between 1989 and 1997. 
The authors found that relative survival (which accounts for competing causes of death) was consistently lower for 
elderly compared to younger patients. The excess mortality among patients aged >75 years was apparent dur-ing the 
first 3 months and after 3 years of diagnosis, with no significant influence of age between 1 and 3 years after diag-
nosis.23 Similarly, in a latter European study on HNC, rela-tive survival was lower among elderly ( 75 years) versus 
younger patients diagnosed from 1999 to 2007.9 In the US, a study from a large university-based cancer registry used 
data from 1990 to 2005 and found that, after adjusting for poten-tial confounders, patients with HNC aged 70 years at 
diag-nosis had a risk of death about twice as high as that of patients younger than 70 years.24 Notably, the authors 
showed that when older patients with advanced disease (stage at diagnosis III–IV) were treated with multimodality 
therapy, 5-year overall survival was close to that of younger patients who received similar therapeutic management. 
However, older patients who received single-modality treatment had dramatically lower 5-year survival than their younger 
coun-terparts. Older age is commonly associated with moderate to severe comorbidities, which may diminish the 
patient’s ability to tolerate surgery and intensive cancer adjuvant treatment, such as radiotherapy and/or 
chemotherapy.10 Comorbidities such as cardiovascular and pulmonary diseases in HNC patients are mostly secondary 
to smoking and excessive alco-  
hol use. In addition, advanced age is associated with a decline in immune function,25–27 which may not only facilitate 
can-  
cer progression but also weaken the host immune response against cancer.10 Nonetheless, studies suggest that as 
cancer is the main cause of death among elderly patients with advanced HNC, the competing causes of death likely 
contrib-ute to a small fraction of the lower survival observed among these patients.24 The main challenge in the 
treatment of elderly patients with HNC is to decide for which patients the benefit of intensive multimodality therapy 
compensates the risk of treatment toxicity. 
Stage at diagnosis is widely considered a main determi-nant of cancer survival and this is also true for HNC.9 Our 
results showed that even with the advance on diagnosis pro-cedures observed in the last decades, the majority of 
patients (55%) with HNC are still diagnosed with advanced disease (stages III–IV) in Europe. This proportion is close to 
the EUROCARE-5 study,9 which used data from 29 European countries on patients diagnosed from 1999 through 2007. 
The authors emphasized that over 54% of patients were diag-nosed with regional or metastatic disease. We found that 
the risk of death was 2 or 3 times greater among patients with stage III or IV, respectively, than those with stage I at diag-
nosis. While HNC can be often cured when diagnosed at early stage, late stage disease may be untreatable or involve 
aggressive multimodality treatment that often leads to severe physical and psychological disabilities. It has been reported 
that HNC has the highest risk of disability and work quitting, together with central nervous system and hematologic 
malignancies.28 
We observed a strong association between smoking and survival. This association was significant for all investigated 
variables (overall smoking history, duration and intensity) and highlights the importance of intensifying tobacco preven-
tion and control in Europe. According to the World Health Organization, smoking kills closely 6 million people per year, 
more than HIV/AIDS, malaria and tuberculosis combined. It has been estimated that this number can increase to over 8 
million people by 2030 if more immediate and severe actions are not taken.29 While some previous studies had shown 
negative30,31 or limited32,33 association between smok-ing and HNC survival, our findings support a large population-
based study conducted in Ireland which revealed that smoking at diagnosis was associated with worse sur-vival.34 The 
authors highlighted that this association was stronger among patients who had surgical treatment for their HNC, and 
neither chemotherapy nor radiotherapy influenced the effect of smoking on survival. One relevant question in the clinical 
setting is whether smoking cessation after cancer diagnosis can improve prognosis of HNC, for instance, decreasing 
treatment complications and the risk of relapse or second primary malignancy.35 Post-treatment smoking his-tory was 
not available in our study. 
While our results support the influence of smoking on survival from HNC, we did not find the same association 
regarding alcohol consumption and survival when we exam-ined overall alcohol history, duration or intensity. Our find-
ings differ from a US study36 which found that alcohol consumption pre- and postdiagnosis adversely affected HNC 
survival, and highlighted the need for aggressive interventions to help patients to abstain from or decrease alcohol 
intake. In another US study,37 which enrolled over 1,000 patients with HNC, about 17% of patients had secondary 
tumors. Strik-ingly, alcohol consumption combined with smoking after diagnosis was found to significantly increase the 
risk of sec-ondary tumors among these patients. More studies in Europe are needed to investigate the association 
between alcohol pre-and postdiagnosis and HNC outcomes.  
In our study, HNC prognosis varied significantly by ana-tomic site, with better survival for larynx, intermediate for oral 
cavity and worse for hypopharynx cancer patients. These results are consistent with previous survival studies in Europe. 
For example, the EUROCARE II study,38 which used data from 17 countries on patients diagnosed from 1985 to 1989, 
revealed that overall, 5-year relative survival was 63% for larynx, 41% for oral cavity and 22% for hypo-pharynx cancer, 
with wide geographic variations (higher sur-vival in Western than Eastern European countries). The authors suggested 
that possible reasons for the observed sur-vival disparities are late diagnosis, late referral to treatment and lack of 
access to effective treatment. The subsequent EUROCARE-5 study9 showed that 5-year relative survival after larynx 
cancer has not improved over time (from 1999– 2001 to 2005–2007), whereas survival improved by 3–5% (absolute 
difference) for oral cavity, oropharynx and hypo-pharynx. However, 5-year relative survival was still low: 25% for 
hypopharynx and 45% for oral cavity cancer patients. Although our results are not directly comparable, the same survival 
pattern was observed in our cohort of patients, sug-gesting no or little improvement in the last few decades, despite 
progresses in diagnosis procedures and therapeutic management. This finding is concerning and emphasizes the need 
for increased healthcare policy aimed at decreasing modifiable risk factors (such as smoking and alcohol con-sumption) 
for HNC occurrence in Europe. 
Curative treatment for HNC is complex and often nega-tively impacts patient’s quality of life (e.g., causing difficulty to 
speak, breath, swallow and facial deformity). Advance-ments in treatment such as new surgical techniques, the use of 
concurrent or alternating chemoradiation, hyperfrac-tionated or accelerated radiotherapy, and more recently 
immunotherapy, may improve HNC survival and reduce the burden of complications secondary to treatment.39 
However, improvement in HNC outcomes have been disap-pointing. Despite treatment advances, larynx cancer is one of 
the few types of cancer in which survival has recently decreased in the US (from 66% during 1975–1977 and 1987–1989 
to 63% during 2005–2011).40 It has been postu-lated that the declining survival trends are due to changes  
in treatment toward a nonsurgical (organ preservation) approach.41,42 
For hypopharynx cancer, a recent population-based study43 using SEER data showed evidence of increasing sur-
vival trends since 1990: 5-year overall survival improved from 38% during 1973–1989 to 41% during 1990–2003. 
Through the study period, there was a trend toward reduced surgical treatment and increased use of radiation-only ther-
apy. In contrast to what has been observed for larynx cancer in the US, this study suggests that organ preservation may 
have a survival benefit for hypopharynx cancer patients. For oral cavity cancer, surgery remains the first-line 
treatment,44 while radiotherapy and lymph node resection are usually per-formed for advanced stage disease or for 
those patients con-sidered ineligible for surgical interventions.  
It has been recognized that 50% of patients with HNC have substantial weight loss at diagnosis and just before start of 
ther-apy in consequence of cancer symptoms (e.g., dysphagia, odynophagia and anorexia),45 and this has been shown 
to nega-tively impact survival.46 Therefore, we aimed to investigate whether BMI 2 years before diagnosis also influence 
survival after HNC. After multiple adjustments, we did not observe a sig-nificant association between the risk of death 
and underweight, which may be explained by the small number of patients in this category (fewer than 3.5%). Similarly, 
overweight or obesity pre-diagnosis was not found to impact survival among our patients.  
Finally, when tumor samples were available, we evaluated whether p16 expression alone or associated with HPV16 
DNA testing predicts prognosis for nonoropharynx cancers. P16 is a tumor suppressor gene considered a good proxy for 
HPV infec-tion in tumors.3 Our results support the lack of an association  
between survival and p16 overexpression examined alone, as reported by other authors.47,48 We also did not find any 
associ-  
ation with survival when p16 was considered with HPV16 DNA testing. It is possible that, in our study, the small number 
of HNC cases that were positive for both HPV16 DNA and p16 has contributed for the negative association we observed. 
Fur-ther studies to investigate the prognostic role of these markers on nonoropharynx cancer outcomes are warranted.  
Our study has several limitations. As the ARCAGE study was initially designed to look at risk factors of head and neck 
cancer, collection of clinical data such as detailed treatment approach and relapse (including dates of treatment and 
relapse) were restricted. Therefore it was not possible to inves-tigate the impact of treatment modality on survival or 
relapse. We used self-reported weight and height 2 years before diagno-sis, which may be subject to inaccuracy and 
bias. However, pre-vious studies have shown high correlation (r > 0.9) between self-reported and measured height, 
weight and BMI.49,50 Over-all, data were missing on stage at diagnosis in about 21% of cases. However, the strong 
association we found between stage at diagnosis and survival supports previous studies and empha-sizes the impact of 
late diagnosis on HNC prognosis. Although Rome did not have information on certain variables, the data provided by this 
center were valuable and the associations we found remained even when these cases were excluded from the analyses. 
We also lacked information on comorbidities, perfor-mance status and treatment complications. Although these data 
would likely have contributed additional findings, predic-tors of HNC outcome such as smoking, stage and age at diag-
nosis are of paramount importance and were clearly demonstrated in our study. In addition, the strengths of the 
ARCAGE study includes a standard protocol, data from several European centers with detailed information on smoking 
and alcohol histories, tumor histological or cytological confirmation for all patients and blood and tumor samples for 
several cases.  
In summary, HNC is a complex malignancy that involves vital anatomic structures, which make it difficult to treat. 
Surprisingly, despite the advances in diagnosis and therapeutic modalities, sur-vival after HNC remains low in Europe. 
Most patients continue to be diagnosed with disease at advanced stage, which often requires aggressive treatment and 
may lead to substantial disabil-ities and psychological disorders, reducing quality of life among survivors. The association 
between older age and inferior survival suggests that treatment should be personalized based on patients’ comorbidities 
and tolerability. Importantly, public health efforts in Europe should focus on primary prevention to deter the initia-tion of 
tobacco use, promote smoking cessation and prevent excessive alcohol consumption. Furthermore, secondary preven-
tion to detect HNC at an earlier stage is crucial. 
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